On-body delivery systems for subcutaneous isatuximab could enable patient self-administration, according to Xavier Leleu, MD, PhD, improving convenience and transforming treatment for ...

The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, ...

Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, ...

Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment ...